Next-Generation Bispecific Nanobody Therapy Targeting EGFR and FCGR3A for Colorectal Cancer

VHH-P320 is a bispecific, humanized nanobody-based therapeutic designed to target both the epidermal growth factor receptor (EGFR) and Fc gamma receptor IIIa (FCGR3A). Currently in the Biological Testing stage, VHH-P320 leverages advanced antibody engineering, including Fc modifications and single-domain antibody integration, to enhance immune engagement against tumor cells. By simultaneously engaging EGFR, a key driver of colorectal cancer pathogenesis, and FCGR3A, critical for natural killer cell activity, VHH-P320 offers a promising mechanism for targeted immunotherapeutic intervention in colorectal cancer.

Licensing Opportunity

VHH-P320 is available for out-licensing and strategic collaboration. Partners interested in innovative, next-generation bispecific nanobody therapeutics for oncology indications are invited to engage for co-development or licensing opportunities.

Development Phase

Modality

VHH-P320 utilizes a bispecific format, combining a humanized IgG1 kappa antibody against EGFR with an alpaca-derived, humanized anti-CD16 single-domain nanobody, further enhanced by fusion to IL-15 and its receptor sushi domain. The nanobody component confers unique structural benefits such as small size, high stability, and superior tissue penetration compared to conventional antibodies. These features enable VHH-P320 to access dense tumor environments more efficiently and maintain robust functionality under physiological conditions, offering a promising approach for the treatment of colorectal cancer.

Target

EGFR and FCGR3A are the critical molecular targets of VHH-P320. EGFR is a transmembrane tyrosine kinase involved in cellular proliferation and survival, extensively expressed in epithelial tissues and frequently overexpressed in colorectal cancer. FCGR3A is an activating receptor predominantly found on immune effector cells such as natural killer cells, mediating antibody-dependent cellular cytotoxicity. Aberrant activity of EGFR contributes to colorectal cancer progression and resistance, while targeting FCGR3A harnesses innate immunity for tumor cell eradication. By simultaneously engaging EGFR and FCGR3A, VHH-P320 strategically combines targeted tumor cell recognition with potent immune activation, addressing key pathogenic mechanisms in colorectal cancer and enhancing its potential as a leading-edge therapeutic asset.

Mechanism of Action

VHH-P320 exerts its therapeutic effect by binding to EGFR on tumor cells and to FCGR3A on natural killer cells. Through dual engagement, it bridges tumor and immune cells, facilitating NK cell-mediated cytotoxicity via FCGR3A activation and disrupting EGFR-driven signaling in colorectal cancer. This bispecific nanobody also incorporates immune-activating domains, such as IL-15 and receptor components, further enhancing immune cell recruitment and function. The modular nanobody platform used in VHH-P320 supports future development as an antibody-drug conjugate or other bi-specific constructs, offering versatility for addressing the evolving therapeutic landscape in oncology.

Colorectal Cancer

Colorectal cancer is among the most prevalent malignancies globally, contributing significantly to cancer mortality. It commonly arises from epithelial cells lining the colon or rectum and displays considerable molecular and clinical heterogeneity. Standard treatments include surgery, chemotherapy, radiotherapy, and targeted biologics; however, recurrence and resistance remain major challenges. Limitations of current therapies include non-specific toxicity, limited efficacy in metastatic disease, and the emergence of resistance mutations. There remains substantial unmet medical need for more selective and potent therapeutics. VHH-P320, with its dual-targeting approach, addresses this unmet need by combining precision targeting of EGFR-positive tumor cells with innate immune activation through FCGR3A, positioning it as a promising candidate for patients with advanced or refractory colorectal cancer.